Foundation Medicine Inc (NASDAQ:FMI) Director Michael J. Pellini sold 37,288 shares of the firm’s stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $64.55, for a total transaction of $2,406,940.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Foundation Medicine Inc (FMI) opened at $67.25 on Friday. The stock has a market cap of $2,470.00, a price-to-earnings ratio of -15.04 and a beta of -0.01. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.24 and a quick ratio of 2.03. Foundation Medicine Inc has a 52 week low of $18.00 and a 52 week high of $74.30.

Foundation Medicine (NASDAQ:FMI) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.16. The business had revenue of $42.66 million for the quarter, compared to the consensus estimate of $37.99 million. Foundation Medicine had a negative net margin of 119.69% and a negative return on equity of 143.18%. Foundation Medicine’s quarterly revenue was up 45.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.90) earnings per share. research analysts expect that Foundation Medicine Inc will post -4.44 EPS for the current year.

Several equities research analysts have recently issued reports on FMI shares. Zacks Investment Research upgraded shares of Foundation Medicine from a “hold” rating to a “buy” rating and set a $59.00 price objective on the stock in a research note on Monday, November 6th. BidaskClub upgraded shares of Foundation Medicine from a “hold” rating to a “buy” rating in a research note on Tuesday, December 12th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. Foundation Medicine has a consensus rating of “Hold” and an average price target of $45.33.

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Foundation Medicine by 8.2% in the second quarter. Vanguard Group Inc. now owns 631,339 shares of the company’s stock worth $25,096,000 after purchasing an additional 47,843 shares during the period. Peregrine Capital Management LLC bought a new position in Foundation Medicine in the third quarter worth $13,299,000. TIAA CREF Investment Management LLC lifted its position in Foundation Medicine by 9.8% in the second quarter. TIAA CREF Investment Management LLC now owns 39,000 shares of the company’s stock worth $1,550,000 after purchasing an additional 3,490 shares during the period. Macquarie Group Ltd. lifted its position in Foundation Medicine by 33.3% in the third quarter. Macquarie Group Ltd. now owns 106,603 shares of the company’s stock worth $4,285,000 after purchasing an additional 26,603 shares during the period. Finally, Northern Trust Corp lifted its position in Foundation Medicine by 7.4% in the second quarter. Northern Trust Corp now owns 187,714 shares of the company’s stock worth $7,462,000 after purchasing an additional 12,881 shares during the period. Institutional investors and hedge funds own 32.68% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2018/01/21/foundation-medicine-inc-fmi-director-sells-2406940-40-in-stock.html.

Foundation Medicine Company Profile

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.